The characteristics of cancerous patients infected with COVID-19 in hospital setting.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
10 11 2020
10 11 2020
Historique:
received:
08
07
2020
accepted:
03
08
2020
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
9
3
2021
Statut:
epublish
Résumé
Recently, Covid 19 as a fatal virus has been known as the cause of the pandemic. Different number of the mortality rate in various societies have been reported. However, it seems the underlying comorbidities increase the risk of mortality and the severity of presentation. In this study we evaluated the pattern of presentation of COVID-19 among cancerous patients in terms of severity. between 20th February to 22nd April of 2020, among 214 hospitalized patients because of COVID-19. 41 patients revealed the cancer as a synchronous comorbidity. These patients based on the severity of COVID-19 infection presentation were divided to mild and severe groups. Then, the demographic characteristics, manifestation and laboratory data between these groups were compared. about 19 (46.34%) of 41 cases were categorized as severe forms of COVID-19 with malignancy. The mean age of severe groups was significantly higher (P=0.00). Dyspnea (48.78%), cough (46.34%) and myalgia (24.39%) were the most common clinical features among cancerous patients with COVID-19. diarrhea and nearly cough caused significant effects on severe form of presentation of COVID-19 infection (P=0.05, P=0.06, respectively). Hematological cancers were the most frequent types of cancer among these patients (46.34%). White Blood Cell counts were significantly lower in severe groups (P=0.03, P=.0.06, respectively). C-reactive protein is another item that nearly significantly was higher in severe groups of cancerous patients (P=0.06). The elderly age, the positive chemotherapy history, diarrhea, cough, declined WBC, PLT and elevated CRP correlated with a severe form of this infection in malignant cases.
Identifiants
pubmed: 33525203
doi: 10.23750/abm.v91i4.10175
pmc: PMC7927459
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2020145Références
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
JCO Oncol Pract. 2020 May;16(5):223-225
pubmed: 32302270
J Infect. 2020 Aug;81(2):318-356
pubmed: 32298677
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
Arch Iran Med. 2020 Jul 01;23(7):507-508
pubmed: 32657604
Mol Cancer. 2020 Apr 28;19(1):80
pubmed: 32345328
Acta Biomed. 2020 Sep 07;91(3):e2020005
pubmed: 32921703
J Med Virol. 2020 Sep;92(9):1533-1541
pubmed: 32181903
Nat Rev Clin Oncol. 2020 Jun;17(6):329-331
pubmed: 32296166
Arch Bone Jt Surg. 2020 Apr;8(Suppl 1):247-255
pubmed: 32733980
Arch Iran Med. 2020 Jul 01;23(7):505-506
pubmed: 32657603
Eur Respir J. 2020 May 14;55(5):
pubmed: 32299866
Cureus. 2020 Mar 27;12(3):e7434
pubmed: 32351814
BMJ. 2020 Mar 27;368:m1270
pubmed: 32220899
Curr Oncol Rep. 2020 May 8;22(5):53
pubmed: 32385672
J Clin Virol. 2020 May;126:104345
pubmed: 32278298
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977